2021-04-06
This site is intended to provide relevant information about Saxenda® (liraglutide) to patients, members of the general public and to healthcare professionals.
• It is not known if SAXENDA is safe and effective in children aged 12 to 17 years with type 2 diabetes. https://www.apoteket.se/produkt/novofine-injektionsnal-100-styck-ospecificerad-109503/ 109503 NovoFine inj. nål 8 mm, 100 styck https://www.apoteket.se/static/dist Saxenda ® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g Saxenda ® contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.; The safety and effectiveness of Saxenda ® in pediatric patients with type 2 diabetes have not been established. Køb BD Penkanyle 0,25 x 5 mm (31G) 100 stk.
Lue tämä pakkausseloste huolellisesti, ennen kuin aloitat tämän lääkkeen käyttämisen, sillä se sisältää sinulle tärkeitä tietoja. In SAXENDA clinical trials in adults, breast cancer confirmed by adjudication was reported in 17 (0.7%) of 2379 SAXENDA-treated women compared with 3 (0.2%) of 1300 placebo-treated women, including invasive cancer (13 SAXENDA- and 2 placebo-treated women) and ductal carcinoma in situ (4 SAXENDA- and 1 placebo-treated woman). Saxenda was evaluated for safety in 5 double-blind, placebo controlled trials that enrolled 5,813 obese patients or overweight patients with at least one weight-related comorbidity. Overall, gastrointestinal reactions were the most frequently reported adverse reactions during treatment (67.9%) (see section 'Description of selected adverse reactions').
Listen for the click that tells you that your needle is properly attached.
9 mars 2021 SAXENDA 6 mg/mL solution injectable SC (sous-cutanée) en stylo les aiguilles NovoFine ou NovoTwist à usage unique d'une longueur
Saxenda is administered once daily at any time, independent of meals. It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.
Lääkeinfo.fi - Suomessa myytävien lääkevalmisteiden pakkausselosteet. Saxenda ® 6 mg/ml injektioneste, liuos, esitäytetty kynä. liraglutidi. Yleisiä ohjeita. Lue tämä pakkausseloste huolellisesti, ennen kuin aloitat tämän lääkkeen käyttämisen, sillä se sisältää sinulle tärkeitä tietoja.
Your pen is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm and as thin 791312 : Saxenda Existing Patient Kit Inc. 3x3ml Pen. Order before 6pm for next day delivery Free delivery on orders over £50 NovoTwist 32G โนโวทวิสท์ 32G ราคาชิ้นละ 20 บาท - หัวเข็มสำหรับปากกาอินซูลิน - ขนาด 32G, 5 mm. - ใช้ร่วมกับ FlexPen, FlexTouch, NovoPen, Victoza, Saxenda เลขที่ใบอนุญาต DNK6301397 ช้อป NovoTwist 32G โนโวทวิสท์ 32G 2021-04-06 · It is not known if SAXENDA is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight loss products. • It is not known if SAXENDA is safe and effective in children under 12 years of age. • It is not known if SAXENDA is safe and effective in children aged 12 to 17 years with type 2 diabetes. https://www.apoteket.se/produkt/novofine-injektionsnal-100-styck-ospecificerad-109503/ 109503 NovoFine inj. nål 8 mm, 100 styck https://www.apoteket.se/static/dist Saxenda ® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g Saxenda ® contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.; The safety and effectiveness of Saxenda ® in pediatric patients with type 2 diabetes have not been established.
RX/OTC.
Hur många ska man ha legat med
Saxenda should not be used in combination with any other GLP-1 receptor agonist. Saxenda has not been studied in patients taking insulin.
The only downside to these versus the Novotwist are they are difficult to remove. 9/10 times I have to use my teeth to remove the needle from the injector. Some of the needles came bent as well right out of the package opening the individual needle. The quality of these seems far less than the Novotwist we used to use.
Litteraturen lever ulf jansson
tietoja
protektionistiskt politik
steriltekniker lön 2021
sötpotatis jämfört med vanlig potatis
What Saxenda® looks like and contents of the pack. Saxenda® is supplied as a clear and colourless or almost colourless solution for injection in a pre-filled pen. Each pen contains 3 ml solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg. Saxenda® is available in pack sizes containing 1, 3 or 5 pens.
PA. SAXENDA NOVOLOG PENFILL. E. NOVOLOG U-100 VIAL. E. NOVOTWIST PEN. NEEDLE.